Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

TNKASE DIN 02562804

Status: Marketed
Holder: HOFFMANN-LA ROCHE LIMITED
Molecule: TENECTEPLASE

Health Canada record

Active ingredient(s)TENECTEPLASE 25 MG
Dosage formPowder For Solution
RouteIntravenous
SchedulePRESCRIPTION; SCHEDULE D
ClassHuman
ATCB01AD11 TENECTEPLASE
Original market date13-Aug-2026
Current status date13-Aug-2026
SourceHealth Canada DPD

Establishment licence of the holder

Hoffmann-La Roche Limited — licence 100006, currently licensed, last inspection rating C (2024-06-25).

No Canadian shortage report is currently matched to this DIN.

Other Canadian products containing TENECTEPLASE

DINProductCompanyFormStrengthStatus
02244826TNKASEHOFFMANN-LA ROCHE LIMITEDPowder For SolutionTENECTEPLASE 50 MGMarketed

Notices of Compliance

NOCDateSubmissionReason
363662025-11-13Supplement to a New Drug Submission (SNDS)New indication : Intravenous use in adults for the treatment of acute ischemic stroke (AIS). Treatment is to be initiated within 4.5 hours from the onset of AIS symptoms and after exclusion of intracranial haemorrhage. New strength
Request a quote for TNKASE

How to read a Canadian DIN record